Group One Trading
FATE icon

Group One Trading’s Fate Therapeutics FATE Stock Holding History

Group One Trading’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-9,305
Closed -$17.2K – 7855
2026
Q1 		$11.2K Buy
9,305
+4,874
+110% +$5.93K ﹤0.01% 6317
2025
Q4 		$4.35K Buy
4,431
+1,600
+57% +$1.92K ﹤0.01% 7241
2025
Q3 		$3.57K Buy
+2,831
New +$3.05K ﹤0.01% 7698
2025
Q1 		– Sell
-8,728
Closed -$10.7K – 7815
2024
Q4 		$14.4K Buy
8,728
+6,611
+312% +$16.7K ﹤0.01% 5906
2024
Q3 		$7.41K Buy
+2,117
New +$8.24K ﹤0.01% 5731
2024
Q2 		– Sell
-1,050
Closed -$4.6K – 6944
2024
Q1 		$7.71K Sell
1,050
-15,639
-94% -$96.8K ﹤0.01% 6001
2023
Q4 		$62.4K Buy
16,689
+10,400
+165% +$24.5K ﹤0.01% 4891
2023
Q3 		$13.3K Buy
+6,289
New +$20.8K ﹤0.01% 6168
2023
Q1 		– Sell
-2,654
Closed -$16K – 7409
2022
Q4 		$26.8K Buy
2,654
+419
+19% +$7.87K ﹤0.01% 5428
2022
Q3 		$50K Sell
2,235
-9,201
-80% -$266K ﹤0.01% 5402
2022
Q2 		$283K Buy
11,436
+5,200
+83% +$143K ﹤0.01% 3960
2022
Q1 		$242K Buy
+6,236
New +$241K ﹤0.01% 4598
2021
Q3 		– Sell
-5,427
Closed -$426K – 8336
2021
Q2 		$471K Buy
+5,427
New +$437K ﹤0.01% 4281
2020
Q4 		– Sell
-1,691
Closed -$105K – 6637
2020
Q3 		$68K Sell
1,691
-5,373
-76% -$188K ﹤0.01% 4442
2020
Q2 		$242K Sell
7,064
-19,258
-73% -$574K ﹤0.01% 3227
2020
Q1 		$585K Buy
26,322
+23,730
+916% +$600K ﹤0.01% 1942
2019
Q4 		$51K Buy
2,592
+2,328
+882% +$37K ﹤0.01% 3994
2019
Q3 		$4K Sell
264
-1,200
-82% -$23K ﹤0.01% 4805
2019
Q2 		$30K Sell
1,464
-2,900
-66% -$52.3K ﹤0.01% 4020
2019
Q1 		$77K Sell
4,364
-3,361
-44% -$53.1K ﹤0.01% 3338
2018
Q4 		$99K Buy
+7,725
New +$108K ﹤0.01% 3157
2018
Q3 		– Sell
-23,312
Closed -$276K – 5307
2018
Q2 		$264K Buy
+23,312
New +$257K ﹤0.01% 2825

Other funds holding FATE

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Johnson & Johnson
Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $234B AUM 43.58% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Group One Trading's FATE Position: Q2 2026 in Review

Group One Trading sold out of Fate Therapeutics (FATE) in Q2 2026, closing a stake of 9,305 shares — an estimated $17.2K sold.

Group One Trading first reported a position in FATE in Q2 2018 and held it in 22 quarters. The position peaked at $585K in Q1 2020. 157 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • Group One Trading reported no remaining Fate Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Group One Trading sold 9,305 Fate Therapeutics shares in Q2 2026, an estimated $17.2K.
  • Group One Trading first reported a position in Fate Therapeutics in Q2 2018 and held it in 22 quarters.
  • Group One Trading's Fate Therapeutics position peaked at $585K in Q1 2020.
  • 157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.